In immune-compromised mouse models, the use of a GM-CSF-expressing MeV significantly influenced tumor regression, either hastening or delaying it, which was tied to an elevation in neutrophils from the host and an increase in CD3+ T-lymphocytes within the tumor environment [145,146]. This evidence concerns the gene CSF2 and neoplasm.